Wolfe Research downgraded Verona Pharma (VRNA) to Peer Perform from Outperform without a price target after Merck (MRK) announced it will acquire Verona for $10B or $107 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma downgraded to Neutral from Buy at Roth Capital
- Verona Pharma Stock (VRNA) Soars 20% on $10B Merck Deal
- Verona Pharma downgraded to Neutral from Buy at BTIG
- Verona Pharma downgraded to Equal Weight from Overweight at Wells Fargo
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!